Cvt19 Inhibitors

Cvt19 inhibitors can, either directly or indirectly, impact the function or expression of the ATG19/Cvt19 protein. Central to the realm of autophagy, these inhibitors typically exert their effects by meddling with the intricate autophagic machinery, of which ATG19 plays a pivotal role.

Most inhibitors, such as Wortmannin and 3-Methyladenine, target PI3K, a critical kinase involved in the initiation of autophagy. Bafilomycin A1 and Concanamycin A, on the other hand, focus on the latter stages of the autophagy process, particularly the fusion of autophagosomes with lysosomes. This blockage results in a buildup of autophagosomes, thus stunting autophagic flux. Chloroquine follows a similar mechanism by impairing lysosomal acidification. The microtubule-disrupting agent, Vinblastine, impedes the transport of autophagosomes, while agents like Niclosamide disrupt ATP production, affecting cellular energy homeostasis and indirectly autophagy.